Fecal Calprotectin in Patients Infected with Intestinal Protozoan Infections
NCT ID: NCT06890455
Last Updated: 2025-03-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
120 participants
OBSERVATIONAL
2025-03-31
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Nitazoxanide in Patients With Ulcerative Colitis
NCT06993974
Assessment of CMV-specific ELISPOT Assay for Predicting CMV Colitis in Patient With Ulcerative Colitis
NCT02439372
Study of the Interactions Between Dientamoba Fragilis and the Gut Microbiota
NCT02534272
Advanced Metagenomic Analysis of Human Colonic Microbiota in Patients With Chronic GI Disorders
NCT01099111
Fecal Calprotectin: Cheap Marker for Diagnosing Acute Infectious Diarrhea
NCT00429325
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Case group
40 patients complaining of gastrointestinal manifestations and infected with Blastocystis or Entamoeba histolytica
No interventions assigned to this group
Control group 1
40 persons complaining of gastrointestinal manifestations without any protozoal infections
No interventions assigned to this group
Control group 2
\- 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites).
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 40 samples from patients complaining of gastrointestinal manifestations and only infected with B.hominis and E.histolytica.
* 40 samples from patients complaining of gastrointestinal manifestations without any protozoal infection.
* 40 healthy control cross-matched volunteers (without gastrointestinal manifestations, or intestinal parasites).
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sohag University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Youstina Kamel Boles
Demonstrator of Medical parasitology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sohag University
Sohag, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Soh-Med--25-3-07MS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.